UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Haematologica (Roma), 2022-03, Vol.107 (3), p.715-720

2022

Volltextzugriff (PDF)

Age-Adjusted Cutoff D-Dimer Level to Rule Out Acute Pulmonary Embolism A validation cohort study

The American journal of medicine, 2016-08, Vol.129 (8), p.872-878

2016

Volltextzugriff (PDF)

Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

Chest, 2017-03, Vol.151 (3), p.564-571

2017

Volltextzugriff (PDF)

Predicting the risk for major bleeding in elderly patients with venous thromboembolism using the Charlson index. Findings from the RIETE

Journal of thrombosis and thrombolysis, 2021-05, Vol.51 (4), p.1017-1025

2021

Volltextzugriff (PDF)

Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia

Thrombosis research, 2017-03, Vol.151, p.S11-S15

2017

Volltextzugriff (PDF)

P1068: UPDATED RESULTS FROM AN OPEN‐LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD‐1 TREATMENT

HemaSphere, 2023-08, Vol.7 (S3), p.e5990067-n/a

2023

Volltextzugriff (PDF)

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

The American journal of medicine, 2017-04, Vol.130 (4), p.482.e1-482.e9

2017

Volltextzugriff (PDF)

T058: Safety and Dose‐Expansion Study of Combination Favezelimab (anti–LAG‐3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD‐1 Treatment

HemaSphere, 2022-10, Vol.6 (Suppl), p.27-27

2022

Volltextzugriff (PDF)

Extracellular vesicles in hematological disorders

Rambam Maimonides medical journal, 2014-10, Vol.5 (4), p.e0032-e0032

2014

Volltextzugriff (PDF)

Hemostasis and Thrombosis in the Oldest Old

Seminars in thrombosis and hemostasis, 2018-10, Vol.44 (7), p.624-631

2018

Volltextzugriff (PDF)

VTE Registry: What Can Be Learned from RIETE?

Rambam Maimonides medical journal, 2014-10, Vol.5 (4), p.e0037-e0037

2014

Volltextzugriff (PDF)

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

The lancet oncology, 2022-07, Vol.23 (7), p.e334-e347

2022

Volltextzugriff (PDF)

Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis

Thrombosis and haemostasis, 2020-07, Vol.120 (7), p.1128-1136

2020

Volltextzugriff (PDF)

Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer

European journal of internal medicine, 2021-07, Vol.89, p.132-134

2021

Volltextzugriff (PDF)

Disease dynamics in patients with acute myeloid leukemia: New biomarkers

Experimental hematology, 2015-11, Vol.43 (11), p.936-943

2015

Volltextzugriff (PDF)

Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors

Thrombosis and haemostasis, 2022-09, Vol.122 (9), p.1594-1602

2022

Volltextzugriff (PDF)

Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism

The American journal of medicine, 2018-09, Vol.131 (9), p.1095-1103

2018

Volltextzugriff (PDF)

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.4440-4440

2023

Volltextzugriff (PDF)

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Blood, 2023-11, Vol.142 (Supplement 1), p.2014-2014

2023

Volltextzugriff (PDF)

The age-adjusted D-dimer cutoff level to rule out pulmonary embolism in patients with syncope

European journal of internal medicine, 2022-03, Vol.97, p.125-127

2022

Volltextzugriff (PDF)

Microvesicles microRNAs Reflect and Affect Progression of Acute Myeloid Leukemia and Could Serve As a Biomarker of Disease Dynamics

Blood, 2016-12, Vol.128 (22), p.1664-1664

2016

Volltextzugriff (PDF)

Statin use and 30‐day mortality in patients with acute symptomatic pulmonary embolism

Journal of thrombosis and haemostasis, 2022-08, Vol.20 (8), p.1839-1851

2022

Volltextzugriff (PDF)

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7545-7545

2022

Volltextzugriff (PDF)

Attenuated humoral immune response following anti‐SARS‐CoV‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis

American journal of hematology, 2021-12, Vol.96 (12), p.E475-E478

2021

Volltextzugriff (PDF)

Eosinophilic pleocytosis in the cerebrospinal fluid following CAR-T cell therapy for CNS lymphoma: A case for warning?

Acta haematologica, 2024-05

2024

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(74)

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Age-Adjusted Cutoff D-Dimer Level to Rule Out Acute Pulmonary Embolism A validation cohort study

Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

Predicting the risk for major bleeding in elderly patients with venous thromboembolism using the Charlson index. Findings from the RIETE

Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia

P1068: UPDATED RESULTS FROM AN OPEN‐LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD‐1 TREATMENT

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

T058: Safety and Dose‐Expansion Study of Combination Favezelimab (anti–LAG‐3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD‐1 Treatment

Extracellular vesicles in hematological disorders

Hemostasis and Thrombosis in the Oldest Old

VTE Registry: What Can Be Learned from RIETE?

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis

Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer

Disease dynamics in patients with acute myeloid leukemia: New biomarkers

Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors

Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

The age-adjusted D-dimer cutoff level to rule out pulmonary embolism in patients with syncope

Microvesicles microRNAs Reflect and Affect Progression of Acute Myeloid Leukemia and Could Serve As a Biomarker of Disease Dynamics

Statin use and 30‐day mortality in patients with acute symptomatic pulmonary embolism

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study

Attenuated humoral immune response following anti‐SARS‐CoV‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis

Eosinophilic pleocytosis in the cerebrospinal fluid following CAR-T cell therapy for CNS lymphoma: A case for warning?

Suchergebnisse filtern